Sponsor Overview
Explore verified public information about University of Washington's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 3 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 3 supporting sources.
“These documents provide instructions for UW physicians who wish to use an investigational drug, device or biologic for clinical treatment of a single patient. FHCC physicians may use this process for emergency, but not compassionate uses.”
“This webpage describes the IRB-related requirements and procedures for the mechanisms that allow expanded access to investigational drugs, devices, and biologics for clinical (not research) purposes before the items have been approved by the Food and Drug Administration (FDA) for use and marketing.”
“The University of Washington requires its health care providers and its IRBs to comply with all applicable regulations of the Food and Drug Administration (FDA) when using investigational drugs, biologics, and devices for clinical purposes.”
Past EAPs on ClinicalTrials.gov
Score contribution: 40 — 4 supporting sources.
Conditions: Solid Tumor, Adult
Conditions: Erythrocytosis, Familial, 2
Conditions: Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation, Triple-Negative Breast Cancer
Conditions: Cancer of the Prostate
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.